secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytosorbents Corp (CTSO)
CIK:        0001175151
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001104659-24-084908
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoSorbents regains Nasdaq minimum bid price compliance
--------------------------------------------------------

- Received Nasdaq letter on July 26, 2024 confirming compliance after closing bid price at $1.00+ for 10 consecutive days through July 25.
- Previously, on May 22, 2024, Nasdaq notified CytoSorbents of non-compliance due to bid price below $1.00 for 30 consecutive days.
- Compliance had to be achieved by November 16, 2024; the company regained compliance early from July 12 to July 25.
- CEO Dr. Phillip Chan stated the company is now in full compliance, strengthening its position ahead of expected DrugSorb-ATR regulatory submissions.
- CytoSorbents continues aggressive cost cutting and operational progress on clinical, regulatory, and manufacturing fronts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175151/000110465924084908/0001104659-24-084908-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175151/000110465924084908/tm2420569d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-084908

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer